ICU Skin Decolonisation May Raise Resistant Infections
Universal skin decolonisation of patients admitted to intensive care units (ICU) may not improve infection control. New research led by the University of Aberdeen indicated that it might increase meticillin-resistant Staphylococcus epidermidis (MRSE) bloodstream infections in vulnerable patients.
Hospital-associated infections cause significant morbidity and mortality, with critically ill patients in ICUs at particularly high risk. Surveillance figures from English ICUs show an ICU-associated bloodstream infection rate of 3.5 per 1000 bed-days for stays of two nights or more in the year to March 2024. Over 25% of patients with these infections die within 30 days.
Reasons for the increased infection rate in ICUs include high antibiotic use leading to significant skin flora colonisation by resistant bacteria. Invasive procedures including indwelling catheters and the insertion of intravascular devices are independently associated with meticillin-resistant Staphylococcus aureus (MRSA) colonisation and infection.
Need for a New Infection Control Approach
Decolonisation protocols were introduced in the 1990s to curb rising nosocomial MRSA infections due to MRSA. Nationwide infection control programmes since the mid-2000s led to sharp declines in MRSA rates in NHS hospitals over the next decade. One UK-wide study in ICU patients between 2007 and 2016 showed a 78% decrease in bloodstream infections overall and a 97% reduction in MRSA bloodstream infections.
However, data from the National Institute for Health and Care Research show this decline plateaued after 2012. Rates have subsequently been largely static, suggesting the need for a new approach.
Routine ICU decolonisation typically involves chlorhexidine skin disinfection combined with nasal mupirocin. The Aberdeen team noted conflicting evidence on chlorhexidine's effectiveness. They also raised concerns that biocide skin and mucous membrane decolonisation might lead to reduced susceptibility to chlorhexidine and selection for multidrug-resistant pathogens.
Study Compares Universal and Targeted Decolonisation
The researchers compared universal versus targeted skin and nasal decolonisation in ICU patients at two Scottish hospitals in adjacent health boards with different protocols. The study included patients aged 16 years and over admitted between 1 July 2009 and 28 Feb 2022.
One hospital switched from universal decolonisation of all admissions to targeting only MRSA carriers from 1 February 2019. The other hospital used targeted decolonisation throughout. The researchers analysed rates of S. epidermidis bloodstream infections and tested MRSE and chlorhexidine susceptibility.
Results Show Benefits in Reducing Resistant Infections
The results, published in The Lancet Microbe , showed that S epidermidis was identified in 334 (45%) of 735 bloodstream infections in the hospital that de-escalated decolonisation. Of these, 197 occurred before de-escalation. Overall, bloodstream infection rates did not increase after de-escalation.
However, MRSE infections declined significantly after the switch – from 10.4 to 4.3 cases per 1000 occupied bed days. The probability of MRSE among infections fell from 89.2% to 56.7%.
By contrast, the control hospital reported 167 (60%) S. epidermidis bloodstream infections among 278 total, with no significant changes in infection rates or MRSE incidence.
Genetic analyses revealed de-escalation was linked to fewer bloodstream infections caused by multidrug-resistant S. epidermidis strains. There was reduced carriage of mobile genetic elements and genes related to multidrug resistance and biofilm production.
Balancing Benefits and Risks
"In ICU settings with low MRSA incidence, the benefits of universal decolonisation should be balanced against the risks of selecting MRSE sequence types adapted for invasive and device-associated infection," the researchers concluded.
Professor Karolin Hijazi, chair in oral and maxillofacial medicine at the University of Aberdeen and study lead, commented in a press release: "This research essentially demonstrates that the excess use of disinfectants in universal decolonisation offered no advantage in terms of control of serious blood infections in a low MRSA ICU setting, but instead caused the unintended rise of MRSE bloodstream infections."
Implications for Infection Control Policy
The authors recommended that hospitals consider the "unintended harms of universal decolonisation", especially given the global rise of antimicrobial resistance. Hijazi added that such practices increase resistance risks and costs without added benefit in low-MRSA settings.
The findings should inform standardised national guidelines for effective and safe patient decolonisation, in line with the government's 5-year action plan for antimicrobial resistance, the researchers said. They described the emergence and spread of antimicrobial resistance as a 'silent pandemic' and stressed that reducing unnecessary decolonisation could help contain resistance and reduce costs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
40 minutes ago
- Medscape
Cancer Concerns Spark Caution Over Weight Loss Injections
Cancer patients should seek medical advice before using weight loss injections, a leading UK charity has said. Macmillan Cancer Support urged patients not to view these drugs as 'quick fixes', following a rise in helpline queries over whether they should take them. Obesity is a well-established risk factor for several cancer types and is linked to worse outcomes in patients who already have a cancer diagnosis. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have seen rapid uptake for weight loss. Their popularity has helped fuel speculation that they could reduce the risk of cancer or improve outcomes in people with obesity-related cancers. Mixed Findings on Cancer Risk and Benefits A study published in The Lancet eClinical Medicine in May compared outcomes in patients treated with GLP-1 RAs versus bariatric surgery. The research involved 3178 age- and BMI-matched pairs in Israel. Despite surgery achieving greater weight loss, both groups had similar rates of obesity-related cancers. The researchers suggested that there could be additional pathways beyond weight loss through which GLP-1RAs might lower cancer risk, for example by reducing inflammation. Other experts have proposed additional pathways, including enhanced immune responses, improved insulin sensitivity, hormonal modulation, and changes to gut microbiome. As a result of the study, clinical trials of GLP-1RAs as potential anti-cancer agents are planned. Potential Risks: Thyroid and Pancreatic Cancer Some studies have suggested that GLP-1RAs carry a minor increase in the risk of thyroid cancer, which is one of the 13 cancers known to be linked with obesity. Some GLP-1RAs now carry warnings about this potential link, although the evidence is conflicting. One meta-analysis of 64 studies by Italian researchers, published in March 2024, found a significant increase overall thyroid cancer risk. However, the data did not show a significant rise in papillary or medullary thyroid cancer when analysed separately. The researchers concluded that GLP-1RA treatment could be associated with a moderate increase in the relative risk of thyroid cancer, though the absolute risk remained small. They called for longer-term studies to clarify the link. In contrast, a Scandinavian cohort study published in April found no substantial increase in thyroid cancer risk over an average follow-up of 3.9 years. The authors said the findings did not rule out a slight increase but suggested no more than a 31% relative risk rise. Similar concerns have been raised about a theoretical risk of pancreatic cancer, but no conclusive evidence has been found. Macmillan Helpline Sees Spike in Inquiries Following recent media coverage, Macmillan Cancer Support reported a surge in calls and messages about weight loss medications, including the potential risk to people with thyroid cancer. Dr Owen Carter, Macmillan's national clinical adviser, said in a press release that there had been "a noticeable increase" in calls to the charity's free support line, alongside "a flurry of messages" on its peer-to-peer online community platform. In response, the charity has published updated information about weight loss injections and cancer on its website. Carter said that some callers were concerned about taking weight loss drugs while undergoing cancer treatments such as chemotherapy or hormone therapy. While there is currently not enough evidence, "we do know that these drugs may affect how other drugs are absorbed by your body," he said. "This may include some anti-cancer drugs." Weight Loss Before Surgery and Pre-habilitation Other patients have asked whether weight loss medication is safe to take before surgery for cancer. "Understandably, people are keen to do what they can to get ready for cancer treatment," Carter said. Healthcare professionals often recommend pre-habilitation to help patients prepare for treatment by improving their fitness and overall health. However, Carter warned against unprescribed use of weight loss injections as 'quick fixes'. 'We simply do not know enough about the long-term impact of these weight loss medications to recommend them if they're not prescribed by a specialist,' he said. Carter also emphasised the importance of making lifestyle changes alongside use of medications. "We know that eating well and staying as active as possible are proven to help people feel better, increase their energy levels, and strengthen their immune systems, which can help them to manage their weight and cope better with cancer treatment", he said. Risks of Unregulated Online Purchases Macmillan also raised concerns about people buying GLP-1 RAs online from unregulated sources. Some patients are reported to have experienced severe side effects from counterfeit medicines. The charity urged people to speak to their GP before taking weight loss drugs. Macmillan noted that potential side-effects of GLP-1RAs include nausea and vomiting, abdominal pain, diarrhoea or constipation, and fatigue. They can also reduce the effectiveness of oral contraceptives. There have been reports of unplanned pregnancies occurring while taking these drugs, which may be particularly hazardous in cancer patients, as some cancer treatments are teratogenic.
Wall Street Journal
2 hours ago
- Wall Street Journal
Health Insurers to Promise Changes to Preapproval Process That Drew Backlash
Following the backlash that hit health insurers after the killing of a top executive last year, the industry will pledge steps meant to smooth the controversial preapproval process that can deny or delay access to care. The initiative is set to be unveiled early next week, according to people familiar with the matter.
CNN
2 hours ago
- CNN
Dozens in northeast England report symptoms of potentially deadly botulism after getting Botox
Health officials in the UK are investigating reports of dozens of people suffering from a potentially life-threatening condition following Botox procedures in northeastern England, as well as allegations of the illegal sale of Botox-like products. The local trust of the UK's National Health Service (NHS) in the county of Durham put out an alert on June 13 about several people seeking medical attention after having adverse reactions to cosmetic procedures involving Botox. Since the incident first came to light last week, 28 individuals have reported symptoms of botulism after receiving cosmetic procedures, the UK Health and Security Agency (UKHSA) told CNN in a statement Friday. Botulism is a life-threatening condition caused by toxins made by Clostridium botulinum bacteria that attack the nervous system and cause paralysis. 'These toxins (but not the bacteria) are the active ingredient in Botox and similar products,' Dr. Joanne Darke, a consultant in health protection at the UKHSA, said in the statement, adding that it is 'important to go to a licensed practitioner.' Iatrogenic botulism is a type of botulism that occurs when too much of the cosmetic form, Botox, is injected into a muscle. Botox is a leading cosmetic treatment for wrinkles, as well as for medical conditions such as migraines and excessive sweating. The UKHSA said the reactions reported have included symptoms of severe drooping of the upper eyelids, double vision, difficulty swallowing, slurred speech and lethargy. Other symptoms of botulism can include facial muscle weakness. Botulism requires immediate medical attention and is fatal in 5-10% of cases, according to the NHS website. While most people make a full recovery with treatment, which typically involves getting injections with antitoxins, without quick care, paralysis can spread to muscles used to control breathing. While investigations into the cause of the cases are ongoing, the UKHSA said that 'evidence so far does not suggest that the product used has been contaminated. Symptoms are being reported a few days up to four weeks after injection.' 'The practitioners associated with most of the reported cases are no longer carrying out these procedures,' said Dr. Simon Howard, a consultant in health protection at the UKHSA, in the statement. 'However, that does not mean that we may not see more cases as symptoms can take up to four weeks to develop although we are now seeing the number of cases coming forward decreasing which is encouraging news,' he continued. Howard advised people to ensure they take precautions when seeking aesthetic procedures and advised anyone with symptoms to seek medical attention. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) told CNN Friday that it is investigating 'allegations surrounding the illegal sale and supply of Botox-type products in the North-East, and want to reassure the public that we take such claims very seriously.' The agency encouraged people in the UK who believe they have had side effects from medicine or received falsified stock to report it to its Yellow Card program. 'Our Criminal Enforcement Unit works hard to identify those involved in the illegal trade in medicines and takes robust enforcement action where necessary. This can include criminal prosecution,' Dr. Alison Cave, chief safety officer at MHRA, said in the statement. 'Botulinum toxin (Botox) is a prescription-only medicine and should only be available in the UK under the supervision of a doctor or other qualified healthcare professional,' she continued. In the United States, a growing cluster of botulism cases linked to cosmetic injections was reported in Massachusetts earlier this month. The state's Department of Health said it was investigating 10 cases of suspected iatrogenic botulism all associated with Botox procedures performed at one spa, Rodrigo Beauty.
